Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>

Common stock purchase or sale:
Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
2025-07-10 Sale | 2025-07-11 6:17 pm | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 934 | $125 | $116,750 | 46,456 (Direct) | View |
2025-06-23 Sale | 2025-06-24 8:29 pm | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 500 | $114.08 | $57,042 | 31,903 (Direct) | View |
2025-06-10 Sale | 2025-06-12 5:51 pm | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 500 | $114.54 | $57,271 | 32,403 (Direct) | View |
2025-05-15 Sale | 2025-06-02 8:06 pm | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 1,000 | $104 | $104,000 | 32,903 (Direct) | View |
2025-05-09 Purchase | 2025-05-13 8:05 pm | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 9,510 | $105.2 | $1,000,456 | 161,234 (Direct) | View |
2025-05-09 Purchase | 2025-05-13 8:04 pm | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 1,500 | $104.06 | $156,090 | 27,932 (Direct) | View |
2025-03-04 Sale | 2025-03-06 6:55 pm | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 5,000 | $115.03 | $575,149 | 59,080 (Direct) | View |
2024-12-23 Sale | 2024-12-26 8:32 pm | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 2,104 | $116.37 | $244,850 | 20,647 (Direct) | View |
2024-11-27 Sale | 2024-12-02 8:05 pm | LIGAND PHARMACEUTICALS INC | LGND | LAMATTINA JOHN L Director | 2,406 | $123.65 | $297,502 | 29,515 (Direct) | View |
2024-09-23 Sale | 2024-09-25 8:54 pm | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 2,000 | $99.6 | $199,201 | 93,478 (Direct) | View |
2024-09-20 Sale | 2024-09-24 7:41 pm | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 1,275 | $103.94 | $132,518 | 24,610 (Direct) | View |
2024-09-20 Sale | 2024-09-24 7:41 pm | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 16,047 | $102.35 | $1,642,359 | 93,608 (Direct) | View |
2024-08-28 Sale | 2024-08-30 8:56 pm | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 1,500 | $106.39 | $159,591 | 83,978 (Direct) | View |
2024-08-22 Sale | 2024-08-26 8:15 pm | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 18,858 | $105.34 | $1,986,420 | 49,510 (Direct) | View |
2024-08-09 Sale | 2024-08-13 5:21 pm | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 18,245 | $98.5 | $1,797,133 | 68,368 (Direct) | View |
2024-08-08 Purchase | 2024-08-09 5:52 pm | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 2,500 | $97.39 | $243,481 | 123,010 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
2025-07-01 Conversion | 2025-07-03 09:33 am | N/A N/A | Pelthos Therapeutics Inc. | PTHS | LIGAND PHARMACEUTICALS INC 10% Owner | 1,500,000 | $10 | 1,537,279 (Direct) | View |
2025-07-01 Other | 2025-07-03 09:33 am | N/A N/A | Pelthos Therapeutics Inc. | PTHS | LIGAND PHARMACEUTICALS INC 10% Owner | 31,279 | $0 | 1,537,279 (Direct) | View |
2025-07-01 Conversion | 2025-07-03 09:33 am | N/A N/A | Pelthos Therapeutics Inc. | PTHS | LIGAND PHARMACEUTICALS INC 10% Owner | 15,000 | $0 | 1,537,279 (Direct) | View |
Ownership | 2025-07-03 09:28 am | N/A N/A | Pelthos Therapeutics Inc. | PTHS | LIGAND PHARMACEUTICALS INC 10% Owner | 0 | $0 | 1,800,000 (Direct) | View |
2025-06-30 Other | 2025-07-02 7:32 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 233 | $91.08 | 32,369 (Direct) | View |
2025-06-30 Other | 2025-07-02 7:32 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 224 | $91.08 | 30,076 (Direct) | View |
2025-06-30 Other | 2025-07-02 7:31 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 233 | $91.08 | 161,700 (Direct) | View |
Ownership(A) | 2025-07-02 7:03 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 0 | $0 | 1,696 (Direct) | View |
2025-06-06 Option Award | 2025-06-10 7:39 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Gray Nancy Ryan Director | 6,992 | $0 | 13,877 (Direct) | View |
2025-06-06 Option Award | 2025-06-10 7:39 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Aryeh Jason Director | 6,992 | $0 | 141,691 (Direct) | View |
2025-06-06 Option Award | 2025-06-10 7:24 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | LAMATTINA JOHN L Director | 6,992 | $0 | 36,507 (Direct) | View |
2025-06-06 Option Award | 2025-06-10 7:21 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Zimmermann Martine Director | 6,992 | $0 | 10,341 (Direct) | View |
2025-06-06 Tax Withholding | 2025-06-10 7:21 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Zimmermann Martine Director | 188 | $105.99 | 10,341 (Direct) | View |
2025-06-06 Option Award | 2025-06-10 7:21 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Sabba Stephen L Director | 6,992 | $0 | 39,576 (Direct) | View |
2025-06-06 Option Award | 2025-06-10 7:21 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 6,992 | $0 | 53,173 (Direct) | View |
2025-06-06 Option Award | 2025-06-10 7:20 pm | N/A 2035-06-06 | LIGAND PHARMACEUTICALS INC | LGND | Haas Jason Director | 6,992 | $0 | 12,389 (Direct) | View |
2024-08-10 Tax Withholding | 2025-06-02 8:06 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 897 | $100.16 | 32,903 (Direct) | View |
2025-01-17 Exercise | 2025-06-02 8:05 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 2,406 | $52.3 | 46,181 (Direct) | View |
2025-01-17 Exercise | 2025-06-02 8:05 pm | N/A 2025-04-24 | LIGAND PHARMACEUTICALS INC | LGND | KOZARICH JOHN W Director | 2,406 | $0 | 46,181 (Direct) | View |
2025-04-01 Exercise | 2025-04-16 09:34 am | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Sabba Stephen L Director | 2,406 | $52.3 | 32,584 (Direct) | View |
2025-04-01 Exercise | 2025-04-16 09:34 am | N/A 2025-04-24 | LIGAND PHARMACEUTICALS INC | LGND | Sabba Stephen L Director | 2,406 | $0 | 32,584 (Direct) | View |
2025-03-04 Option Award | 2025-03-06 6:55 pm | N/A 2035-03-04 | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 34,458 | $0 | 62,826 (Direct) | View |
2025-03-04 Option Award | 2025-03-06 6:55 pm | N/A 2035-03-04 | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 40,201 | $0 | 59,080 (Direct) | View |
2025-03-04 Option Award | 2025-03-06 6:54 pm | N/A 2035-03-04 | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 114,858 | $0 | 245,200 (Direct) | View |
2025-02-14 Option Award | 2025-02-19 8:44 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 20,784 | $0 | 130,342 (Direct) | View |
2025-02-14 Tax Withholding | 2025-02-19 8:44 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Davis Todd C Chief Executive Officer | 13,452 | $120 | 130,342 (Direct) | View |
2025-02-14 Option Award | 2025-02-19 8:38 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 12,819 | $0 | 23,879 (Direct) | View |
2025-02-14 Tax Withholding | 2025-02-19 8:38 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 9,587 | $120 | 23,879 (Direct) | View |
2025-02-14 Option Award | 2025-02-19 8:37 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 12,357 | $0 | 28,368 (Direct) | View |
2025-02-14 Tax Withholding | 2025-02-19 8:37 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 6,523 | $120 | 28,368 (Direct) | View |
2024-12-05 Tax Withholding | 2024-12-06 7:55 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 1,859 | $123.51 | 22,751 (Direct) | View |
2024-11-27 Exercise | 2024-12-02 8:05 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | LAMATTINA JOHN L Director | 2,406 | $52.3 | 29,515 (Direct) | View |
2024-11-27 Exercise | 2024-12-02 8:05 pm | N/A 2025-04-24 | LIGAND PHARMACEUTICALS INC | LGND | LAMATTINA JOHN L Director | 2,406 | $0 | 29,515 (Direct) | View |
2024-09-23 Exercise | 2024-09-25 8:54 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 2,000 | $52.27 | 93,478 (Direct) | View |
2024-09-23 Exercise | 2024-09-25 8:54 pm | N/A 2032-08-01 | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 2,000 | $0 | 93,478 (Direct) | View |
2024-09-23 Exercise | 2024-09-24 7:41 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 9,377 | $52.84 | 93,608 (Direct) | View |
2024-09-20 Exercise | 2024-09-24 7:41 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 5,377 | $49.99 | 93,608 (Direct) | View |
2024-09-20 Exercise | 2024-09-24 7:41 pm | N/A 2026-02-11 | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 14,754 | $0 | 93,608 (Direct) | View |
2024-09-17 Exercise | 2024-09-19 5:50 pm | N/A 2030-10-01 | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 1,486 | $0 | 33,591 (Direct) | View |
2024-09-17 Exercise | 2024-09-19 5:50 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 1,417 | $80.72 | 33,591 (Direct) | View |
2024-09-17 Exercise | 2024-09-19 5:50 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 69 | $57.22 | 33,591 (Direct) | View |
2024-09-16 Exercise | 2024-09-18 7:55 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 849 | $58.49 | 114,348 (Direct) | View |
2024-09-16 Tax Withholding | 2024-09-18 7:55 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 3,214 | $105 | 114,348 (Direct) | View |
2024-09-16 Exercise | 2024-09-18 7:55 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 914 | $55.75 | 114,348 (Direct) | View |
2024-09-16 Exercise | 2024-09-18 7:55 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 3,340 | $60.94 | 114,348 (Direct) | View |
2024-09-16 Exercise | 2024-09-18 7:55 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 671 | $49.99 | 114,348 (Direct) | View |
2024-09-16 Exercise | 2024-09-18 7:55 pm | N/A 2026-02-11 | LIGAND PHARMACEUTICALS INC | LGND | Korenberg Matthew E President & COO | 5,774 | $0 | 114,348 (Direct) | View |
2024-08-28 Exercise | 2024-08-30 9:00 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 546 | $70.04 | 31,708 (Direct) | View |
2024-08-28 Exercise | 2024-08-30 9:00 pm | N/A 2030-10-01 | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 753 | $0 | 31,708 (Direct) | View |
2024-08-28 Exercise | 2024-08-30 9:00 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Espinoza Octavio Chief Financial Officer | 207 | $57.22 | 31,708 (Direct) | View |
2024-08-28 Exercise | 2024-08-30 8:56 pm | N/A N/A | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 1,500 | $52.27 | 83,978 (Direct) | View |
2024-08-28 Exercise | 2024-08-30 8:56 pm | N/A 2032-08-01 | LIGAND PHARMACEUTICALS INC | LGND | Reardon Andrew CLO & Secretary | 1,500 | $0 | 83,978 (Direct) | View |